SCHEMBL10076434

SCHEMBL10076434

C#CCN(C)C(Cc1ccc(C)cc1)CN(C)/C=C\C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.39
PYCR1 P32322 1/20 0.36
MAPT P10636 1/20 0.36
MAOA P21397 7/20 0.35
CYP1A2 P05177 2/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
ADRA1A P35348 1/20 0.34
SNCA P37840 1/20 0.34
OPRK1 P41145 1/20 0.34
CYP2D6 P10635 1/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ACHE P22303 2/20 0.33
KCNQ4 P56696 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10076438 0.87 MAOB (0.45) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL15762035 0.75 MAOB (0.41) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076436 0.73 MAOB (0.40) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076413 0.72 MAOB (0.54) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076437 0.70 MAOB (0.54) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076396 0.69 PYCR1 (0.44) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL12532745 0.69 MAOB (0.46) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076395 0.68 MAOB (0.48) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076435 0.68 MAOB (0.46) MAOBPYCR1MAOACYP1A2ADRA2A
SCHEMBL10076451 0.66 PYCR1 (0.49) MAOBPYCR1MAOACYP1A2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015909-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY JENRIN DISCOVERY (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015909-A1 MAO-B INHIBITORS USEFUL FOR TREATING OBESITY MAOB, MAOA, GPR119 MAOB 1/4885PYCR1 987/4885MAPT 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.